Esophageal Cancer

>

Latest News

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

July 10th 2025

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer
Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

No fatalities were observed with fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin when treating esophageal squamous cell carcinoma.
Fruquintinib Combo Exhibits Frontline Efficacy in Advanced ESCC

June 1st 2025

The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.
Phase 3 IDeate-Esophageal01 Trial Initiated for Unresectable ESCC

May 19th 2025

According to comparative single-cell transcriptome analyses, NOTCH1 deficiency facilitated a more immunologically active microenvironment in ESCC tumors.
NOTCH1 Mutational Status May Predict ICI Outcomes in Esophageal Cancer

April 28th 2025

Video Interviews
Podcasts

More News